Pharmaceutical company perspectives on current safety risk communications in Japan

Hisashi Urushihara, Gen Kobashi, Hideaki Masuda, Setsuko Taneichi, Michiko Yamamoto, Takeo Nakayama, Koji Kawakami, Tsutomu Matsuda, Kaori Ohta, Hiroki Sugimori

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In 1987, a group infection of hepatitis in patients receiving a contaminated fibrinogen product was first reported to the Japanese regulatory agency. Eventually, this serious drug incident involved more than 10,000 cases of infection. In response, the Government of Japan established a responding inspection committee in 2008 to make recommendations for the restructuring of drug regulatory administration. The final report was issued in 2010. One agenda item of this restructuring was the improvement of drug-related safety risk communications. Our research group on drug safety risk communications, which is funded by the Government of Japan, surveyed pharmaceutical companies regarding their perspective on current risk communications. The survey was conducted using an anonymous questionnaire developed for this study which included the three operational domains of targets, contents, and measures of drug risk communication. Fifty-two of the 74 member companies of the Post-marketing Surveillance Subcommittee of the Japan Pharmaceutical Manufacturer's Association participated, and this response rate of more than 70% was considered sufficient to ensure the external validity of the survey results. Results showed that the most highly prioritized aspect of risk messaging was the strength of evidence, and that outcome evaluation of risk communication gained recognition. Further, while physicians and pharmacists were the most prioritized communication targets, pharmacovigilance departments devoted the most resources to regulators, at more than 30%. The Internet was recognized as a useful public source of risk information, whereas Drug Guides for Patients delivered on the web were considered under-recognized. Further discussion of these results with the aim of enhancing the restructuring of the Japanese drug regulatory administration system are warranted.

Original languageEnglish
Article number51
Pages (from-to)1-11
Number of pages11
JournalSpringerPlus
Volume3
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Keywords

  • Drug company
  • Drug risk
  • Questionnaire survey
  • Regulation
  • Safety communication

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Pharmaceutical company perspectives on current safety risk communications in Japan'. Together they form a unique fingerprint.

  • Cite this

    Urushihara, H., Kobashi, G., Masuda, H., Taneichi, S., Yamamoto, M., Nakayama, T., Kawakami, K., Matsuda, T., Ohta, K., & Sugimori, H. (2014). Pharmaceutical company perspectives on current safety risk communications in Japan. SpringerPlus, 3(1), 1-11. [51]. https://doi.org/10.1186/2193-1801-3-51